Clinical trial for lab-grown neo-bladder to help spinal cord injury patients

Urologists at Thomas Jefferson University Hospital are studying whether a neo-bladder construct grown from a patient's own cells can improve bladder function for adult spinal cord injury patients.

Jefferson is only one of six sites in the U.S. enrolling participants in this clinical trial for the lab-grown neo-bladder construct that will involve a total of 10 patients.

“It's never been done in adults before,” said primary investigator Patrick Shenot, M.D., instructor in Urology, Jefferson Medical College of Thomas Jefferson University, noting that a similar study is being conducted with children with spina bifida.

The neo-bladder constructs are being developed by Tengion, Inc. in their pilot manufacturing facility.

Each neo-bladder construct consists of a biodegradable scaffold seeded with urothelial and smooth muscle cells cultured in Tengion's facility from the patient's own bladder cells.

To participate in the study, a patient must be 18 to 65 years of age, have had a spinal cord injury for more than a year and diagnosed with a neurogenic bladder that is not adequately responding to medical therapy.

The urologist first performs a biopsy on the patient to retrieve the cells. The cells are then sent to Tengion's manufacturing facility where they are grown in culture and then seeded onto a biodegradable scaffold in the shape of a bladder.

Then, the patient returns to hospital and the urologist will implant the neo-bladder construct in a procedure known as augmentation cystoplasty or bladder augmentation.

“The neo-bladder is expected to continue to regenerate within the patient, using the body's inherent regenerative capabilities, and if successful may result in improved bladder function,” Dr. Shenot noted.

The field of regenerative medicine is anticipated to be an area of intense interest and expansion in the coming years, said Dr. Shenot.

“While this first trial in adults is for patients with bladder control problems due to spinal cord injury, the possibilities for expansion into oncology related areas are promising,” he said.

http://www.jeffersonhospital.org/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients